BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 26161395)

  • 1. Expression of FOXP3, CD14, and ARG1 in Neuroblastoma Tumor Tissue from High-Risk Patients Predicts Event-Free and Overall Survival.
    Stigliani S; Croce M; Morandi F; Scaruffi P; Rigo V; Carlini B; Manzitti C; Gigliotti AR; Tonini GP; Pistoia V; Ferrini S; Corrias MV
    Biomed Res Int; 2015; 2015():347867. PubMed ID: 26161395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-expression analysis identifies long noncoding RNA SNHG1 as a novel predictor for event-free survival in neuroblastoma.
    Sahu D; Hsu CL; Lin CC; Yang TW; Hsu WM; Ho SY; Juan HF; Huang HC
    Oncotarget; 2016 Sep; 7(36):58022-58037. PubMed ID: 27517149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL-10 and ARG-1 concentrations in bone marrow and peripheral blood of metastatic neuroblastoma patients do not associate with clinical outcome.
    Morandi F; Croce M; Cangemi G; Barco S; Rigo V; Carlini B; Amoroso L; Pistoia V; Ferrini S; Corrias MV
    J Immunol Res; 2015; 2015():718975. PubMed ID: 25961062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of urokinase plasminogen activator and its receptor in metastasis and invasion of neuroblastoma.
    Li P; Gao Y; Ji Z; Zhang X; Xu Q; Li G; Guo Z; Zheng B; Guo X
    J Pediatr Surg; 2004 Oct; 39(10):1512-9. PubMed ID: 15486896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene-environment interactions between CD14 C-260T and endotoxin exposure on Foxp3+ and Foxp3- CD4+ lymphocyte numbers and total serum IgE levels in early childhood.
    Williams LK; Oliver J; Peterson EL; Bobbitt KR; McCabe MJ; Smolarek D; Havstad SL; Wegienka G; Burchard EG; Ownby DR; Johnson CC
    Ann Allergy Asthma Immunol; 2008 Feb; 100(2):128-36. PubMed ID: 18320914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IGF2BP1 harbors prognostic significance by gene gain and diverse expression in neuroblastoma.
    Bell JL; Turlapati R; Liu T; Schulte JH; Hüttelmaier S
    J Clin Oncol; 2015 Apr; 33(11):1285-93. PubMed ID: 25753434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Revised risk estimation and treatment stratification of low- and intermediate-risk neuroblastoma patients by integrating clinical and molecular prognostic markers.
    Oberthuer A; Juraeva D; Hero B; Volland R; Sterz C; Schmidt R; Faldum A; Kahlert Y; Engesser A; Asgharzadeh S; Seeger R; Ohira M; Nakagawara A; Scaruffi P; Tonini GP; Janoueix-Lerosey I; Delattre O; Schleiermacher G; Vandesompele J; Speleman F; Noguera R; Piqueras M; Bénard J; Valent A; Avigad S; Yaniv I; Grundy RG; Ortmann M; Shao C; Schwab M; Eils R; Simon T; Theissen J; Berthold F; Westermann F; Brors B; Fischer M
    Clin Cancer Res; 2015 Apr; 21(8):1904-15. PubMed ID: 25231397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Société Francaise d'Oncologie Pédiatrique.
    Rubie H; Hartmann O; Michon J; Frappaz D; Coze C; Chastagner P; Baranzelli MC; Plantaz D; Avet-Loiseau H; Bénard J; Delattre O; Favrot M; Peyroulet MC; Thyss A; Perel Y; Bergeron C; Courbon-Collet B; Vannier JP; Lemerle J; Sommelet D
    J Clin Oncol; 1997 Mar; 15(3):1171-82. PubMed ID: 9060561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TH and DCX mRNAs in peripheral blood and bone marrow predict outcome in metastatic neuroblastoma patients.
    Yáñez Y; Hervás D; Grau E; Oltra S; Pérez G; Palanca S; Bermúdez M; Márquez C; Cañete A; Castel V
    J Cancer Res Clin Oncol; 2016 Mar; 142(3):573-80. PubMed ID: 26498952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study.
    George RE; London WB; Cohn SL; Maris JM; Kretschmar C; Diller L; Brodeur GM; Castleberry RP; Look AT
    J Clin Oncol; 2005 Sep; 23(27):6466-73. PubMed ID: 16116152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic impact of MYCN, DDX1, TrkA, and TrkC gene transcripts expression in neuroblastoma.
    de Souza DR; Sanabani SS; de Souza AC; Filho Odone V; Epelman S; Bendit I
    Pediatr Blood Cancer; 2011 May; 56(5):749-56. PubMed ID: 21154590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Notch pathway down-regulation with Triple Negative/Basal-like breast carcinomas and high tumor-infiltrating FOXP3+ Tregs.
    Ortiz-Martínez F; Gutiérrez-Aviñó FJ; Sanmartín E; Pomares-Navarro E; Villalba-Riquelme C; García-Martínez A; Lerma E; Peiró G
    Exp Mol Pathol; 2016 Jun; 100(3):460-8. PubMed ID: 27118257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD4/CD8 + T cells, DC subsets, Foxp3, and IDO expression are predictive indictors of gastric cancer prognosis.
    Li F; Sun Y; Huang J; Xu W; Liu J; Yuan Z
    Cancer Med; 2019 Dec; 8(17):7330-7344. PubMed ID: 31631566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Expression and significance of programmed cell death ligand-1 in neuroblastoma tissues].
    Liao R; Sun XF; Zhen ZZ; Huang DS
    Zhonghua Er Ke Za Zhi; 2018 Oct; 56(10):735-740. PubMed ID: 30293276
    [No Abstract]   [Full Text] [Related]  

  • 15. MicroRNA-149 is associated with clinical outcome in human neuroblastoma and modulates cancer cell proliferation through Rap1 independent of MYCN amplification.
    Xu Y; Chen X; Lin L; Chen H; Yu S; Li D
    Biochimie; 2017 Aug; 139():1-8. PubMed ID: 28456710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical characteristics and prognosis of high-risk neuroblastoma with bone marrow metastasis in children].
    Fan HJ; Huang C; Su Y; Wang XD; Zhou YC; Duan C; Zhao W; Zhao Q; Jin M; Ma XL
    Zhonghua Er Ke Za Zhi; 2019 Nov; 57(11):863-869. PubMed ID: 31665841
    [No Abstract]   [Full Text] [Related]  

  • 17. WT1 expression is inversely correlated with MYCN amplification or expression and associated with poor survival in non-MYCN-amplified neuroblastoma.
    Masserot C; Liu Q; Nguyen E; Gattolliat CH; Valteau-Couanet D; Bénard J; Huber C; Ségal-Bendirdjian E
    Mol Oncol; 2016 Feb; 10(2):240-52. PubMed ID: 26482175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calreticulin expression in neuroblastoma--a novel independent prognostic factor.
    Hsu WM; Hsieh FJ; Jeng YM; Kuo ML; Chen CN; Lai DM; Hsieh LJ; Wang BT; Tsao PN; Lee H; Lin MT; Lai HS; Chen WJ
    Ann Oncol; 2005 Feb; 16(2):314-21. PubMed ID: 15668290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression quantitative trait loci and receptor pharmacology implicate Arg1 and the GABA-A receptor as therapeutic targets in neuroblastoma.
    Hackett CS; Quigley DA; Wong RA; Chen J; Cheng C; Song YK; Wei JS; Pawlikowska L; Bao Y; Goldenberg DD; Nguyen K; Gustafson WC; Rallapalli SK; Cho YJ; Cook JM; Kozlov S; Mao JH; Van Dyke T; Kwok PY; Khan J; Balmain A; Fan Q; Weiss WA
    Cell Rep; 2014 Nov; 9(3):1034-46. PubMed ID: 25437558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of the immune microenvironment in resected non-small cell lung cancer: the prognostic value of different T lymphocyte markers.
    Usó M; Jantus-Lewintre E; Bremnes RM; Calabuig S; Blasco A; Pastor E; Borreda I; Molina-Pinelo S; Paz-Ares L; Guijarro R; Martorell M; Forteza J; Camps C; Sirera R
    Oncotarget; 2016 Aug; 7(33):52849-52861. PubMed ID: 27463005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.